Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone


No votes yet
 
Related
Madrid, 12 March 2024 Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, ROVI), informs of the agreement that has been concluded with...
3 min
12/03/2024
ROVI ACHIEVED OPERATING REVENUE GROWTH OF 1% IN THE FIRST POST-PANDEMIC YEAR Operating revenue increased 1% to 829.5 million euros in...
4 min
27/02/2024
ROVI REPORTS OPERATING REVENUE GROWTH OF 3% FOR THE FIRST NINE MONTHS OF THE FIRST POST-PANDEMIC YEAR Operating revenue increased 3%...
5 min
08/11/2023